The incidence of adverse reactions listed below was determined as follows:
- very often ≥ 1/10;
- often ≥ 1/100, <1/10;
- infrequently ≥1 / 1000, <1/100;
- rarely ≥ 1/10 000, <1/1000;
- Very rarely <1/10 000, including individual messages.
From the central nervous system
Often: dizziness *, headache *.
Rarely: loss of consciousness.
Common violations
Often: asthenia (in patients with CHF), increased fatigue *.
Infrequently: asthenia (in patients with hypertension or angina pectoris).
Mental disorders
Infrequently: depression, insomnia.
Rarely: hallucinations, nightmares.
From the nervous system
Infrequent: increased fatigue, asthenia, dizziness, headache.
Rarely: loss of consciousness.
From the skin
Rarely: hypersensitivity reactions, such as pruritus, rash, hyperemia of the skin.
Very rarely: alopecia. Beta-blockers can contribute to exacerbation of symptoms of psoriasis or cause a psoriasis-like rash.
From the genitourinary system
Rarely: a violation of potency, weakening of libido, Peyronie's disease, cystitis, renal colic, polyuria.
From the side of the musculoskeletal system
Infrequently: muscle weakness, muscle cramps.
From the digestive system
Often: nausea, vomiting, diarrhea, constipation.
Rarely: hepatitis.
On the part of the organs of hematopoiesis
In some cases - thrombocytopenia, agranulocytosis.
From the respiratory system
Infrequent: bronchospasm in patients with bronchial asthma or airway obstruction in anamnesis.
Rarely: allergic rhinitis.
From the sense organs
Rarely: decreased lachrymation (should be considered when wearing contact lenses).
Very rarely: conjunctivitis.
From the side of the hearing organ
Rarely: hearing impairment.
From the side of the cardiovascular system
Very often: bradycardia (in patients with CHF).
Often: aggravation of symptoms of CHF flow (in patients with CHF), sensation of cooling and numbness in the extremities, marked decrease in blood pressure, especially in patients with CHF.
Infrequently: violation AV conductivity; bradycardia (in patients with hypertension or angina pectoris); aggravation of symptoms of CHF flow (in patients with arterial hypertension or angina pectoris), orthostatic hypotension.
Influence on the fetus
Intrauterine growth retardation, hypoglycemia, bradycardia.
From the side of the reproductive system
Rarely: a violation of potency.
Laboratory indicators
Rarely: an increase in the concentration of triglycerides and the activity of "hepatic" transaminases in the blood (aspartate aminotransferase (ACT), alanine aminotransferase (ALT)).
* In patients with hypertension or angina, these symptoms usually appear at the beginning of the course of treatment, are not pronounced and take place within 1-2 weeks after the start of treatment.